REPRODUCTIVE HORMONE LEVELS AND METABOLIC SYNDROME IN WOMEN WITH POLYCYSTIC OVARY SYNDROME IN SANA'A, YEMEN

Libia Sina¹, Alariqi Reem², Wadee Abdullah Al-Shehari³, Wadhah Hassan Edrees⁴,⁵, Raba’a Mohammed Jumaan¹, Samar Naji Abdullah Abdulaziz Al-Tamimi⁶

¹Department of Microbiology, Faculty of medicine and health sciences, Sana’a University, Yemen.
²Department of Microbiology, Harbin Medical University, 157 Baojian Road, Harbin 150081, China.
³Department of Microbiology, Faculty of Medical Sciences, Ibb University, Yemen.
⁴Medical Laboratory Department, College of Medical Sciences, Al-Razi University, Yemen.
⁵Medical Microbiology Department, Faculty of Applied Sciences, Hajjah University, Yemen.
⁶Department of General medicine and surgery, Faculty of Medicine and Healthy sciences, Taiz University, Yemen.

ABSTRACT

Background and Objectives: Polycystic ovary syndromes (PCOs) are the most complex endocrine disorders of the female reproductive system with metabolic and psychiatric manifestations. It affects 5-10% of women of childbearing age. There are paucity of information on PCOs. Therefore the present study aimed at the effect of reproductive hormones, metabolic syndromes, smoking and khat chewing on the PCOs among women in Sana'a.

Subjects and Methods: The study included 45 Yemeni women of the age group 18-45 years with PCOs classified into two groups regarding age: Group I 18-29 years old, Group II 30-45 years old and underwent clinical assessment (waist, BMI and sex hormones, blood pressure, glucose, lipids, and insulin), and transvaginal ultrasound. Clinical data, history of other diseases and data of chewing and smoking also collected. Also the study included 45 healthy control women matched in age with the cases.

Results: The prevalence of MS among PCOs patients was 35% and the most prevalent MS risk factors among PCOs patients were waist circumference (WC) 64.4%, and HDL-C 64.4% respectively, while prevalence of triglycerides (TG), hypertension and fasting blood sugar (FBS) were 28.9%, 20% and 13.3%, respectively. PCOs patients had significant increase in serum levels of luteinizng hormone (LH) (p<0.001), Insulin (p<0.001), HOMA-IR (p<0.001), T testosterone (TT) (p<0.001), DHEA-S (p<0.001) and FBS (p<0.016). Lean PCOs patients had a significant increase in TT than overweight/obese PCOs (p<0.045) and dehydroepiandrosterone sulfate (DHEA-S) was found to be significantly higher in PCOs women with metabolic syndrome compared to PCOs women without hypertension (p<0.023).

Conclusion: There is a relationship between PCO, and reproductive hormone disorder. Patients had significant increases in serum levels of LH, LH/Follicle Stimulating Hormone (FSH), Insulin, TT, and DHEA-S. Also, a relationship was found between the syndrome and infertility, hirsutism, irregular menstruation, polycystic ovaries and multiple sclerosis.

Keywords: Hormones, insulin, metabolic risk factors, polycystic ovary syndrome.

INTRODUCTION

Polycystic ovary syndrome (PCOs) begins during adolescence and gradually transitions to adulthood and its effects persist even post-menopause. Clinical features of PCOs can be categorized in three different groups such as reproductive, metabolic, and psychological; which the most common multifaceted and heterogeneous endocrinopathy disorder among adult women. It estimated to affect 6-8% of females in reproductive age. Chronic anovulation, infertility, clinical evidence of Hyperendrogenism (hirsutism, balding of the male pattern and, acne) and enlarged polycystic ovaries have been characterized by PCOs. PCOs also related to resistance to the action of insulin leading to biochemical disturbance to the metabolism and...
SUBJECTS AND METHODS

Specimen Collection and Processing
A total of 45 diagnosed PCOs women’s between 18-43 years age groups were selected from the department of obstetrics and gynaecology at Al-Kuwait University Hospital, Al-Sabeen Hospital, Al-Mahila hospital and modern international lab in Sana’a. 45women without PCOs were selected as control. The PCOs subject was selected if they had 2 out of 3 criteria met (oligo-volauination and anovulation) excess androgen activity, polycystic ovaries by gynecologic ultrasound, with excluding other endocrine disorders; that may cause similar symptoms like hyperprolactinemia, hypothyroidism, cushing syndrome and congenital adrenal hyperplasia.

Assay
5ml of Venous blood sample was collected after 12 h overnight fasting assayed at 8:00-10:00 AM, during the 3rd-5th day of the menstrual cycle (the only early follicular phase). Nine hormones α-OH progesterone, Dehydroepiandrosterone included sulfate(DHEA-S), thyroid-stimulating hormone, prolactin (PRL), follicle stimulating hormone (FSH), luteinize hormone (LH), insulin and total testosterone(TT)were measured by ELISA technique using commercial kits (Human Germany, DRG International USA, Roche, Germany, Abbott USAs). Glucose, Cholesterol, Triglycerides, HDL-cholesterol (HDL-C) and LDL-cholesterol (LDL-C) were measured by enzymatic colorimetric reaction using commercial kits (Human Germany).

Data collection
The primary data collection technique, i.e., the (self-administered) questionnaire was used to collect the data for cases and controls. Which consists of three parts;
1. The demographic characteristics of the participants;
2. The epidemiological characteristics of the participants and;
3. Medicinal properties of the participants.

Data Analysis
Data analysis was performed using the SPSS software (16.0, SPSS Inc, Chicago, IL), and the significant difference was indicated if (p-value<0.05).Continuous variables were checked for normality using the one-sample Kolmogorov-Smirnoff test; they are expressed as mean±standard deviation (SD). The categorical variables are expressed as percentages. Distributions between groups are compared using the T-test with Bonferroni correction for pairwise comparison. Insulin sensitivity, expressed as the IS, was calculated using mathematical modeling (MN MOD version 3.0) HOMA-IR and HOMA-% β were calculated using the 1996 HOMA2 computer model.

RESULTS
The sample size of this study was 90 women belong to 18-43 years of age group. 45 of them were healthy controls women and 45 PCOs patients; who have been diagnosed based on the 2003 Rotterdam criteria. Hirsutism was found in 43(95.6%), 41(91%), had menstrual irregularity. Percentage of oligomenorrhea, amenorrhea and normal menstrual was 25(55.5%), 16(35.5%) and 4(9%) respectively. Among the 17 infertile patients; 11(24.4%) had primary infertility and 6(13.2%) had secondary infertility. PCO on ultrasound was recorded 42(93.3%) and 3(6.7%) had acne while 3(6.7%) had alopecia, 18(40%) of PCOs patients had acne, while 3(6.7%) had alopecia (Table 1). Menses frequency was significantly higher among PCOs patients than that of healthy controls women (p<0.001). Systolic and diastolic blood pressure was also significantly higher among PCOs women as compared to the healthy control group (p<0.008 and p<0.047) respectively. There were no significant differences in menarche, height, weight, BMI and WHR between PCOs patients and healthy controls (Table 2).
The family history of PCOs was significantly increased among PCOs patients compared to that of healthy controls (p<0.001, p<0.004) respectively. Table 3 depicted the family history of PCOs; were significantly increased among PCOs patients compared to that of healthy controls (p<0.001, p<0.004), respectively. However, smoking was more common among healthy controls than patients (p<0.002). Also, Khat chewing, obesity, family history of obesity and diabetes between two controls and PCOs patients were not significantly different. Table 4 shows the differences between biochemical markers between PCOs patients and healthy control women.

### Table 1: Description of the most important clinical finding of PCOs patients.

| Clinical finding (Variable) | PCOs | No |
|----------------------------|------|----|
|                           | N (%) | N (%) |
| Hirsutism                  | 43(95.6%) | 2(4.4%) |
| Acne                      | 18(40%)  | 27(60%)  |
| Alopecia                  | 3(6.7%)  | 42(93.3%)  |
| Infertility                | 17(37.7%) | - |
| Primary Infertility        | 11(24.4%) | - |
| Secondary Infertility      | 6(13.3%)  | - |
| Menstrual irregularity     | 41(91%)   | 0(0%)       |
| PCO                        | 42(93.3%) | 3(6.7%) |

Mean±SD, n=45, N: number; SD: standard deviation; *p-value < 0.05 considered significant; **p-value <0.001 considered highly significant.

The hormonal disturbance of LH, LH/FSH ratio, T, Testosterone and DEHA-S were statically significant to PCOs patients compared to healthy controls (p<0.001, p<0.001, p<0.001, p<0.001, p<0.001) respectively. Moreover, FBS, Insulin and HOMA-IR were moderate significant to PCOs patients (p<0.020, p<0.001, p<0.001) respectively whereas, there were no significant increase was found in lipid profile among PCOs patients as compared to healthy controls. The difference in FSH level was observed between PCOs patients and controls. Comparison side, at the Prevalence of different characteristics of metabolic syndrome between PCOs patients and healthy control women, was 16(35.6%) vs. 0(0%). The rate of WC indicated that the rate of central obesity was 29(64.4%) vs. 24(53.3%), FBS≥100mg/dl was [6(13.3% vs. 2(4.4%)), Triglycerides≥150mg/dl (13(28.9% vs. 7(15.6%), HDL-C<50 mg/dl was 29.9(64.4% vs. 14(31.1%)) and blood pressure≥130/85 mmHg in PCOs women was (9(20%) vs. 1(2.2%)) respectively. The risk of metabolic syndrome was higher significant among PCOs patients than controls (p<0.002) and no significant differences in the characteristics of metabolic syndrome except blood pressure (p<0.284, p<0.138, p<0.655, vs. p<0.007). Comparison of the prevalence of different characteristics of metabolic syndrome between PCOs patients and healthy control women was 16(35.6%) vs. 0(0%). The rate of WC indicated the rate of central obesity was 29(64.4%) vs. 24(53.3%), FBS≥100mg/dl was (6(13.3% vs. 2(4.4%)), Triglycerides≥150 mg/dl 13(28.9% vs. 7(15.6%), HDL-C<50 mg/dl was 29.9(64.4% vs. 14(31.1%)) and blood pressure≥130/85 mmHg in PCOs women was (9(20%) vs. 1(2.2%), respectively.

### Table 2: Demographic characteristics of both healthy control and polycystic ovary syndrome patients.

| Variables                     | Non-PCOs | PCOs | p-value |
|-------------------------------|----------|------|---------|
| Menarche(years)               | 12.49±2.67| 12.73±1.59| 0.83 |
| Married                       | 20(44.4%) | 17(37.7%) | 0.280 |
| Single                        | 25(55.65)| 28(62.2%) | 0.27 |
| BMI (Kg/m²)                   | 25.37±4.57| 26.85±7.81| 0.26 |
| WHR(cm)                      | 0.81±0.8  | 0.82±0.9  | 0.27 |
| WC(cm)                       | 79.93±11.68| 84.02±17.83| 0.204 |
| Days between menstrual cycle (day) | 25.18±3.05| 86.24±56.59| <0.001**|
| Systolic blood pressure (mmHg) | 114.89±13.71| 124±18.69| 0.008** |
| Diastolic blood pressure (mmHg) | 79.56±9.58| 83.78±9.89| 0.043* |

Mean±SD, n=45, N: number; SD: standard deviation; *p-value < 0.05 considered significant; **p-value <0.001 considered highly significant.

### Table 3: Distribution of risk factors for PCOs in both healthy controls and polycystic ovary syndrome patients.

| Risk factors       | Non-PCOs | PCOs | Odd ratio (95% CL) | p-value |
|--------------------|----------|------|-------------------|---------|
| Smoking            | 16 (35.6%) | 4 (8.9%) | 0.177(0.054-0.584)| 0.002** |
| Chewing Khat       | 17(37.8%) | 10 (22.2%) | 0.471(0.186-1.188)| 0.107 |
| Obesity            | 27 (60%)  | 29 (64.4%) | 1.325(0.566-3.099)| 0.517 |
| Family history of DM | 30 (66.7%) | 24 (53.3%) | 0.571(0.244-1.341)| 0.197 |
| Family history of obesity | 32(71.1%) | 31(68.9%) | 0.900(0.365-2.271)| 0.818 |
| Family history of PCOs | 0 (0%)  | 9(20.0%) | 0.444(0.345-0.557)| 0.004** |

Mean±SD, n=45, N: number; SD: standard deviation; *p-value < 0.05 considered significant; **p-value <0.001 considered highly significant.
Table 4: Description and p-value of the biochemical parameters for both healthy controls and polycystic ovary syndrome patients.

| Parameters          | Normal Range | Non-PCOs | PCOs   | p-Value |
|---------------------|--------------|----------|--------|---------|
| LH (mIU/L)          | (1-18)       | 4.10±1.41| 12.4±6.32| <0.001**|
| FSH(mIU/L)          | (3.0-7.9)    | 6.18±1.30| 6.00±2.25| 0.658   |
| LH:FSH ratio        | (1:1)        | 0.669±0.18| 2.23±1.16| <0.001**|
| T.T (ng/ml)         | (0.06-0.82)  | 0.212±0.107| 0.657±0.614| <0.001**|
| DHEA-S (ng/ml)      | (0.06-0.82)  | 1.61±0.99| 3.28±2.36| <0.001**|
| Insulin (µ/ml)      | (3-17)       | 7.98±3.41| 13.24±9.46| <0.001**|
| F.B.S (mg/dl)       | (70-115)     | 80.78±8.95| 89.89±23.23| 0.02**  |
| HOMA-IR             |              | 1.61±0.76| 3.15±2.86| 0.001**  |
| HOMA-%β             |              | 139.95±53.02| 146±13| 0.590    |
| HOMA-S              |              | 95.99±50.40| 71.75±48.05| 0.022   |
| Cholesterol (mg/dl) | < 200        | 190.67±36.94| 204.98±36.04| 0.06    |
| Triglyceride (mg/dl)| < 150        | 114.73±47.82| 130.78±57.75| 0.155   |
| HDL-C (mg/dl)       | >40          | 44.91±9.15| 46.33±14.71| 0.583   |
| LDL-C (mg/dl)       | <130         | 122.84±30.40| 131.53±36.69| 0.225   |

Mean±SD, n=45, N: number; SD: standard deviation; * p-value < 0.05 considered significant; ** p-value <0.001 considered highly significant.

Figure 1 also showed the comparison prevalence characteristics of metabolic syndrome between PCOs patients and control (healthy) women’s.

Clinical, metabolic characteristics and hormones

The clinical and biochemical characteristics of the 45 patients divided according to age. The obesity markers (BMI, WC) associated more with age (p<0.008, p<0.039) also diastolic blood pressure and HOMA-IR (p<0.037, p<0.004). At the same time, hormonal disturbance of LH, LH:FSH ratio, T. Testosterone were lower significant with age (p<0.048, p<0.007, p<0.004) respectively. Also, no significant difference in systolic blood pressure, FSH, DHEA-S, Insulin, F.B.S, HOMA% β cell, HOMA-S, Cholesterol, Triglyceride, HDL-C, LDL-C with ageing among PCOs patient (Table 6).

Table 5: comparison the prevalence of different characteristics of metabolic syndrome between PCOs patients and healthy control women.

| Variables                  | Non-PCOs | PCOs   | p-Value |
|----------------------------|----------|--------|---------|
| WC ≥ 30(cm)               | 24(53.3%)| 29(64.4%)| 0.284   |
| FBS ≥100( mg/dl)          | 2(4.4%)  | 6(13.3%)| 0.138   |
| Hypertension: SBP/DBP     |          |        |         |
| ≥130/85 (mmHg)            | 1(2.2%)  | 9(20%)  | 0.007*  |
| Dyslipidemia              | 6(13.3%) | 12(26.7%)| 0.114   |
| Triglyceride≤150 (mg/dl)  | 7(15.6%) | 13(28.9%)| 0.128   |
| HDL<50( mg/dl)            | 14(31.1%)| 30(64.4%)| 0.655   |
| Metabolic syndrome        | 0(0%)    | 16(35.6%)| 0.002** |

Mean±SD, n=45, N: number; SD: standard deviation; * p-value < 0.05 considered significant; ** p-value <0.001 considered highly significant.

Table 7 indicates no significance difference in anthropometrics, hormonal profiles and metabolic parameters in two ages groups except insulin and HOMA-IR were more significant in 30-43 year group than smaller groups (18-29 year) (p<0.027, p<0.01) indicated that insulin and HOMA-IR were worse with age.

Rotterdam criteria and the metabolic syndrome criteria: Figure 2 indicates the frequency of the Rotterdam criterion in the two groups of patients, separated by age. The incidence of the individual criteria of the metabolic syndrome show older age group was associated with others manifestations.
DISCUSSION

This study aims to investigate the percentage of infertility among PCOs women in Sana’a Yemen. Study association of PCOs with reproductive hormones and metabolic factors and investigate the association of investigated parameters with smoking and khat chewing. The case study included 45 PCOs women, among which only 17(33.3%) were married and 45 healthy control women, among which 20(44.4%) were married. The case and control groups were similar in their demographic profile, and age ranged 18-43 years.

Mean age of menarche was not different between case and control in (12.73±1.59, 12.73±2.67) respectively. The mean age of menarche is typically between 12 and 13 years. The reported mean age of menarche was similar to previous studies. Among the 45 PCOs patients, only 17(37.8%) were married. All of the married PCOs women were infertile with primary infertility (the individual who have never established a pregnancy) representing 11(24.4%), and secondary infertility (the individual who has conceived previously (including miscarriages) but is currently unable to establish a subsequent pregnancy established a pregnancy) (10) representing 6 (13.3%).

In one of the largest published series of 1,871 women with PCOs, whereas 14% were presented with secondary infertility. This finding was different from a Greek study presenting primary and secondary infertility by 49%, and 26% respectively. Primary infertility is more common among PCOs patients. Irregular menses was found in 41(91.1%) of the total women included in this study, among which 25 (55.6%) had either oligomenorrhea or 16 (35.6%) amenorrhea, while 4 (8.9%) of them still had regular menses. Hirsutism, in general, was the second most common complaint after infertility that the attendants claimed to suffer.
Current study found hirsutism in 95.6% of the studied PCOs women in Sana’a. Prevalence of hirsutism in PCOs generally ranges from 40% to 90% among European and American women. It is common in dark skinned people, and rare in Japanese and Asian females. Another explanation for this discrepancy is the genetically determined differences in skin 5α-reductase activator maybe because of diet and environment. Therefore, acne is common in PCOs; in current study, 40% from the PCOs patients had acne. Also, Alopecia prevalence in current study was 6.7% which is rare manifestation among PCOs patients. Recent results were compatible with previous reports which found the prevalence of alopecia to be 6% - 10%. PCOs and non-PCOs at ultrasound scan was (93.3% and 6.7%) respectively, which meets the Rotterdam criteria of PCOs cases 93%. Family history of PCOs among mothers of patients was markedly significant as compared to controls (p <0.0001). The results of present study are in line with previous investigation reported by Mukherjee et al. On the other hand, there was no significance in a family history of DM and obesity, which were different from studies established in Greeks, United Arab Emirates, and Libya (71%, 75.5%, 82%) respectively. Furthermore, in current study, smoking did not affect androgens (TT and DHEA-S) (p<0.45, p<0.72) among PCOs women. This may be due to recall bias, small sample size, or because women in Sana’a are usually not chronic smokers. Triglyceride, LDL-C was significantly higher while HDL-C was significantly lower among smoker patients as compared to non-smokers. Moreover, there was no association between chewing khat and different hormonal and metabolic parameters measured in the PCOs group. No previous researches were established to estimate the effect of khat on PCOs. Therefore, further studies are needed to confirm or exclude current findings. In general, smoking and khat have not changed in the reproductive hormones and metabolic parameters. In this study, the presence of PCOs was not associated with any differences in FSH level. There is an association with LH levels and LH/FSH ratios were remarkably higher among the PCOs patients as compared to the healthy controls (p<0.001, <0.001). The similar results were reported by previous findings in Makah, Jeddah, Iraq, Thai and Libya. Total testosterone levels were significantly higher in used PCOs patients (p<0.001), also DHEA-S levels increased significantly among PCOs women (p<0.001). In recent study revealed an increase in all MS risk factors as compared to control among which insulin resistance and hypertension were statistically significant. As per NHLBI/AHA criteria, the MS characteristics such as WC 29.9(64.4%), HDL-C 29.9(64.4%), HTN 9 (20%), TGI3 28.9%, FBS 6(13.3%) respectively were recorded in PCOs patients. In recent study, the patient phenotype differed greatly from one another age groups. Age was positively associated with obesity markers (BMI and waist circumference) in women with PCOs. The investigating of PCOs in women of different ages is important because it is now understood the increase metabolic and cardiovascular risk and undoubtedly depend on age. As a result, these age-related changes may affect the observed incidence of PCOs. This study found that Women aged 30-43 years possessed higher BMI and waist than younger women (aged 18-29 years). This study was in agreement with Gu’lekli’s suggestion that PCOs women are susceptible to gain weight as they get older. PCOs is careful to be a polygenic trait, and clinical features of this disorder may change by age, beginning in adolescence until menopause. The transvaginal US PCOs is a standard variant, and the incidence of PCOs in young, healthy women younger than 21 years was as high as 80% in a Danish study. Djuijkers found that the prevalence of PCOs was 84% in young women aged 18–22 years compared to 33% in the age group of 33–37 years suggesting that the prevalence of PCOs is

### Table 7: The association between age, clinical and biochemical variables in the healthy controls group.

| Variables                      | 18-29 year (N=19 ) | 30-43 year (N=26 ) | p-Value |
|-------------------------------|--------------------|--------------------|---------|
| BMI (Kg/m²)                   | 24.50±5.16         | 26.46±4.08         | 0.278   |
| Waist (cm)                    | 77.26±12.82        | 81.88±10.59        | 0.193   |
| WHR                           | 0.807±0.87         | 0.88±0.109         | 0.747   |
| Systolic blood pressure (mmHg)| 113±10.28          | 115±15.88          | 0.545   |
| Diastolic blood pressure (mmHg)| 79.21±8.38         | 79.81±10.53        | 0.893   |
| LH (mIU/L) (1-18)             | 3.70±1.53          | 4.40±1.28          | 0.101   |
| FSH(mIU/L) (3.0-7.9) mIU/L     | 5.85±2.45          | 6.53±1.32          | 0.341   |
| LH/FSH ratio (1:1)            | 5.96±1.55          | 6.33±1.08          | 0.247   |
| T. Testosterone (ng/ml) (0.06-0.82) ng/ml | 0.73±0.67 | 0.41±0.22 | 0.094   |
| DHEA-S (ng/ml) (0.06-0.82) ng/ml | 3.33±2.55 | 3.08±1.57 | 0.829   |
| Insulin (µ/ml) (3-17) µ/ml    | 6.67±3.46          | 8.93±3.10          | 0.027*  |
| F.B.S (mg/dl) (70-115) mg/dl  | 78.01±8.57         | 82.81±8.83         | 0.075   |
| HOMA-β (cell %)               | 138.80±63.60       | 140.17±54.89       | 0.915   |
| HOMA-S                         | 96.71±52.97        | 98.71±64.51        | 0.912   |
| HOMA-IR                        | 1.27±0.63          | 1.86±0.77          | 0.01*   |
| Cholesterol (mg/dl) Up to 200mg/dl | 186.32±34.8        | 193.85±38.78       | 0.506   |
| Triglyceride (mg/dl) Up to 200mg/dl | 104.21±36.20       | 122.42±54.17       | 0.211   |
| HDLC (mg/dl) (40-60) mg/dl    | 44.21±8.95         | 45.42±9.43         | 0.666   |
| LDL-C (mg/dl) (100-160) mg/dl | 121.47±28.16       | 123.85±32.45       | 0.799   |

Mean±SD, N: number; SD: standard deviation; *p-value < 0.05 considered significant; **p-value <0.001 considered highly significant.
lower in older women. Current evidence supports the need to adapt the PCOs criterion in the Rotterdam definition of PCOs to patients' age, as indicated by Duijkers and Kristensensen. Recent study included only patients with Rotterdam PCOs parameters, and the latest guideline indicates that before PCO3 can be diagnosed, all 3 Rotterdam parameters must be present in adolescents. Older patients may be more commonly diagnosed with idiopathic hirsutism diseases due to enhanced ovulation rate.

**CONCLUSION**

The PCOs is hormonal disturbance disease, and there is a strongly associated between PCOs and each of these hormones: T.T, DHEA-S, LH, LH/FSH ratio, insulin and HOMA-IR. The hormonal disturbance was clinically presented among PCOs patients in Sana'a as follows: Hirsutism was the most common symptom, and alopecia was the least common, high parentage of PCOs patients suffer from the irregular menstrual period, all married PCOs women were infertile, high prevalence of polycystic ovary (pearl necklace appearance with(many cysts up on ultrasound examination) among PCOs patients, The most significant predictor of metabolic syndrome in PCOs patients was increased waist circumference and reduced HDL-C, Insulin resistance (HOMA-IR ) was a strong association with PCOs; Obesity was not a risk factor for PCOs. Contrary to previous studies, there was a strong association between the family history of PCOs and presentation of the PCO Syndrome among patients. Chewing khat insignificantly reduced testosterone, DHEA-S, insulin, HOMA-IR, HOMA-β, LH, while increases FSH. No significant association was found between PCOs neither with smoking nor with khat chewing. Therefore, further study should be needed in future to evaluate the effects of smoking and khat on PCOs. No previous researches were established to estimate the effect of khat on PCOs.

**AUTHOR’S CONTRIBUTIONS**

The manuscript was carried out, written, and approved in collaboration with all authors.

**CONFLICT OF INTEREST**

The authors declare that they have no conflict of interest.

**REFERENCES**

1. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BOL. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2016. 31(12):2841-2855. https://doi.org/10.1093/humrep/dev218

2. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010;308(1):41. https://doi.org/10.1186/1741-7015-8-41

3. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. The Lancet 2007;25:370(9588):685–97. https://doi.org/10.1016/S0140-6736(07)61345-2

4. Fedorcsak P, Dale PO, Storeng R, Ahyholm T, Tanbo T. The effect of metformin on ovarian stimulation and **in vitro** fertilization in insulin-resistant women with polycystic ovary-laden syndrome: an open-label randomised cross-over trial. Gynecol Endocrinol 2003;17(3):207–14. https://doi.org/10.1080/gye.17.3.207.214

5. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics 2015: Update. 2016. https://doi.org/10.1161/CIR.0000000000000152

6. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 2018 1; 33(9):1602–18. https://doi.org/10.1093/humrep/dey256

7. Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol 2014;210:203e1-203e5. https://doi.org/10.1016/j.ajog.2014.03.008

8. Singla R, Gupta Y, Khemani M, Aggarwal S. Thyroid disorders and polycystic ovary syndrome: An emerging relationship. Indian J Endocrinol Metab 2015;19(1):25–9. https://doi.org/10.4103/2230-8210.140680

9. Lizzieva N, Suturina L, Walker W, Brakkä S, Gavrilova-Jordan L, Azizia R, Criteria, prevalence, and phenotype of polycystic ovary syndrome. Fertil Steril 2016;106(1):6-15. https://doi.org/10.1016/j.fertnstert.2016.03.003

10. March WA, Moore VM, Wilsson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010;25(2):544-51. https://doi.org/10.1093/humrep/dea399

11. Ayyagari M, Chitela SR, Kolachana V, Obesity, polycystic ovarian syndrome and thyroid dysfunction in women with epilepsy. Ann Indian Acad Neurol 2012;15(2):101-5. https://doi.org/10.4103/0972-2327.94992

12. Al-Ruhailly AD, Malabu UH, Suliman RA. Hirsutism in Saudi females of reproductive age: a hospital-based study. Ann Saudi Med 2008;5. https://doi.org/10.5144/0201.e1-201.e5

13. Messinis IE, Messini CI, Dafopoulos K. Novel aspects of the endocrinology of the menstrual cycle. Reprod Biomed Online 2014; 1; 28(6):714–22. https://doi.org/10.1016/j.rbmo.2014.02.003

14. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome-Part 1. Endocr Pract 2015 Nov; 21(11):1291–300. https://doi.org/10.4158/EP15748.DSRCPT2

15. Diamanti-Kandarakis E, Koulri CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek Island of Lesbos: Hormonal and Metabolic Profile. J Clin Endocrinol Metab 1999; 84(1):4006–11. https://doi.org/10.1210/jcem.84.11.6148

16. Vaidya A, Yadav S, Vaidya A. A study on the clinical and hormonal profile of polycystic ovarian syndrome patients attending a tertiary care hospital: a descriptive cross-sectional study. INMA J Nepal Med Assoc 2020 Nov 58(231):875–8. https://doi.org/10.31729/inma.5694

17. VonWolff M. 2019 Feb 1; 33(1):35–45. https://doi.org/10.1016/j.beem.2018.10.005

18. Starace M, Orlando G, Alessandrinii A, Piraccini BM. Female androgenetic alopecia: an update on diagnosis and management. Am J Clin Dermatol 2020; 21(1):69–84. https://doi.org/10.1007/s00277-019-0879-9

19. Broekmans FJ, Knapp EH, Valkenburg O, Laven JS, Eijkemans MJ, Fauser B. PCO2 according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG Int J Obstet Gynaecol 2006; 113(10):1210–7.
20. Mukherjee S, Maitra A. Molecular and genetic factors contributing to insulin resistance in polycystic ovary syndrome. Indian J Med Res 2010; 131(6):743–60. PMID: 20571162

21. Pramodh S. Exploration of lifestyle choices, reproductive health knowledge, and polycystic ovary syndrome (PCOS) awareness among female Emirates University Students. Int J Womens Health 2020; 12:927–38. https://doi.org/10.2147/IJWH.S272867

22. Najem FI, Elmehdawi RR, Swalem AM. Clinical and biochemical characteristics of polycystic ovary syndrome in Benghazi-Libya: A Retrospective study. Libyan J Med 2008; 3(2):71–4. https://doi.org/10.4176/080122

23. Rao CS, Subash YE. The effect of chronic tobacco smoking and chewing on the lipid profile. J Clin Diagn Res;7(1):31–4. https://doi.org/10.7860/JCDR/2012/5086.2663

24. Al Thomali A, Dagherstani MH, Dagherstani MH, Kaya N, Warqy A. Polymorphic Variations in VDR Gene in Saudi women with and without polycystic ovary syndrome (PCOS) and significant influence of seven polymorphic sites on anthropometric and hormonal parameters. J Med Biochem 2018; 37(4):415–25. https://doi.org/10.2478/jomb-2018-0007

25. Wongwananuruk T, Rattanachaiayonont M, Indhavivadhana S, Leerasiri P, et al. Prevalence and clinical predictors of insulin resistance in reproductive-aged Thai women with polycystic ovary syndrome. Int J Endocrinol 2012; e529184. https://doi.org/10.1155/2012/529184

26. Liang SJ, Hsu CS, Tzeng CR, Chen CH, Hsu MI. Clinical and biochemical presentation of polycystic ovary syndrome in women between the ages of 20 and 40. Hum Reprod. 2011; 26(12):3443–9. https://doi.org/10.1093/humrep/der302

27. Gülekli B, Turhan NO, Senöz S, Kükner S, Oral H, Gökmén O. Endocrinological, ultrasonographic and clinical findings in adolescent and adult polycystic ovary patients: A comparative study. Gynecol Endocrinol 1993; 7(4):273–7. https://doi.org/10.3109/09513599309152512

28. Caanen MR, Peters HE, Ven PMV. Anti-Müllerian hormone levels in adolescence in relation to long-term follow-up for presence of polycystic ovary syndrome. The J Clin End Metabolism 2021;106(3):e1084–e1095 https://academic.oup.com/jcem/article/106/3/e1084/6044223

29. Kristensen SL, Ramlau-Hansen CH, Ernst E, et al. A very large proportion of young Danish women have polycystic ovaries: is a revision of the Rotterdam criteria needed? Hum Reprod 2010; 25(12):3117–22. https://doi.org/10.1093/humrep/deq273

30. Duijkers I, Klipping C. Polycystic ovaries, as defined by the 2003 Rotterdam consensus criteria, are found to be very common in young healthy women. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol 2009; 25-152–60. https://doi.org/10.1080/09513590903247824

31. Elzing MW, Korsen TJM, Rekers-Mombarg LTM, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 2000; 15(1):24–8. https://doi.org/10.1093/humrep/15.1.24